Evaluation of the Effect of Vivostat Platelet Rich Fibrin (PRF) in the Treatment of Diabetic Foot Ulcers—Full Text View—ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT00770939

has been cited by the following article:

• TITLE: Autologous Adipose-Derived Mesenchymal Stem Cells Embedded in Platelet-Rich Fibrin in Diabetic Foot Ulcers

  AUTHORS: Charbel Khalil, Diana Chaker, Rawad Salameh, Yvonne-Elise Germanos, Elie El Kayem, Fady Nader, Jessica Habbouche, Rodrigue Chemaly, Albert Azar, Ahmad Ibrahim

  KEYWORDS: Diabetic Foot Ulcer, Diabetes, Mesenchymal Stem Cells, Adipose Tissue, Platelet Rich Fibrin

  JOURNAL NAME: Open Journal of Regenerative Medicine, Vol.10 No.2, June 30, 2021

  ABSTRACT: Context and Aim: Mesenchymal stem cells (MSCs) and platelet-rich fibrin (PRF) have emerged as ideal candidates for advanced therapies of various therapeutically-challenging diseases; however, their regenerative potential in diabetic foot ulcers (DFU) has not been well determined. In this study, we reviewed our clinical experience in mitigating chronic ulcer complications of diabetic foot through a conventional treatment of autologous adipose-derived MSCs embedded in PRF with pure PRF injections. Materials and Methods: The present study was carried out in 10 patients with an open DFU wound selected over a period of 1 year starting from April 2019. Patients were either injected with PRF alone (Group A) or injected with MSCs derived from adipose tissue (ADMSC) embedded in (PRF (Group B). Results: Patients in Group B had a better healing index when compared to Group A. Conclusion: Use of ADMSC embedded in PRF showed promising results to treat DFU.